Bolt biotherapeutics presents preclinical results for next-generation boltbody™ isacs targeting cea and pd-l1 at aacr annual meeting 2025

Cea-targeted isac elicits complete responses in mice and is well-tolerated in nhps pd-l1 isac directly activates and reprograms pd-l1-expressing myeloid cells in the tme to drive complete responses and immunological memory redwood city, calif., april 30, 2025 (globe newswire) -- bolt biotherapeutics (nasdaq: bolt), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced preclinical results from its next-generation boltbody™ isacs targeting ceacam5 and pd-l1 at the american association for cancer research (aacr) annual meeting.
CEA Ratings Summary
CEA Quant Ranking